Uniqure NV (NASDAQ:QURE) was the target of some unusual options trading activity on Monday. Stock investors purchased 3,000 call options on the company. This represents an increase of approximately 1,251% compared to the typical volume of 222 call options.
A number of institutional investors have recently added to or reduced their stakes in QURE. Renaissance Technologies LLC raised its holdings in Uniqure by 48.8% during the 1st quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after purchasing an additional 122,700 shares during the last quarter. Morgan Stanley raised its holdings in Uniqure by 14.9% during the 1st quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after purchasing an additional 73,418 shares during the last quarter. Mangrove Partners raised its holdings in Uniqure by 167.4% during the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after purchasing an additional 66,763 shares during the last quarter. FMR LLC raised its holdings in Uniqure by 4.1% during the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after purchasing an additional 61,650 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Uniqure during the 3rd quarter worth approximately $399,000. Hedge funds and other institutional investors own 24.87% of the company’s stock.
A number of research analysts recently issued reports on QURE shares. HC Wainwright set a $28.00 price objective on shares of Uniqure and gave the company a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research lowered shares of Uniqure from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. Leerink Swann raised their price target on shares of Uniqure from $19.00 to $26.00 in a report on Tuesday, November 7th. Oppenheimer restated a “hold” rating on shares of Uniqure in a report on Friday, November 24th. Finally, ValuEngine lowered shares of Uniqure from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $19.29.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
What are top analysts saying about Uniqure? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Uniqure and related companies.